GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GSK said it acquired an experimental therapy from Chimagen Biosciences that it aims to test in different forms of lupus, and ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

Painkiller brands Panadol and Anadin will be bought under one roof under a giant deal between drug firms GlaxoSmithKline and Pfizer. The firms are combining their consumer healthcare businesses ...

Haleon was formed in July 2019 through the merger of GlaxoSmithKline’s (GB:GSK) and Pfizer’s consumer healthcare businesses. Subsequently, in July 2022, GSK spun off Haleon as an independent ...

The shots are important for both Pfizer and GSK as they look to build new franchises before top-selling drugs face generic competition later this decade. Pfizer is also contending with activist ...

Pfizer is raising around $3.5 billion from the sale of part of its stake in consumer-healthcare business Haleon. The pharmaceutical giant is reducing its shareholding in Haleon to 22.6% from 32% ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

Pfizer and Mylan have announced an all-stock ... formed a joint venture for consumer health with GlaxoSmithKline, and agreed an $11.4 billion deal to acquire cancer specialist Array BioPharma.

Pfizer’s CEO Ian Read is resisting investor pressure to mastermind the next pharma mega-merger, saying that ... after bidders Reckitt Benckiser and GlaxoSmithKline pulled out.

Now, Novartis (Swiss) and GlaxoSmithKline (British ... about whether anything can really be a merger of equals - although while AstraZeneca may be the smaller company (its $87bn market cap is less ...